669 results on '"Gilbertson, Richard J"'
Search Results
52. Table S1 from Establishing a Preclinical Multidisciplinary Board for Brain Tumors
53. Supplementary Table 1 from Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d'Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)
54. Supplementary Table 1 from Genetic Alterations in Mouse Medulloblastomas and Generation of Tumors De novo from Primary Cerebellar Granule Neuron Precursors
55. Supplementary Figure 2 from Genetic Alterations in Mouse Medulloblastomas and Generation of Tumors De novo from Primary Cerebellar Granule Neuron Precursors
56. Supplementary Figure Legends 1-2 from Genetic Alterations in Mouse Medulloblastomas and Generation of Tumors De novo from Primary Cerebellar Granule Neuron Precursors
57. Supplementary Figure 1 from Genetic Alterations in Mouse Medulloblastomas and Generation of Tumors De novo from Primary Cerebellar Granule Neuron Precursors
58. Correction to: DNA methylation signature is prognostic of choroid plexus tumor aggressiveness
59. DNA methylation signature is prognostic of choroid plexus tumor aggressiveness
60. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants
61. Future Treatments of Ependymoma
62. Brain Cancer Stem Cells as Targets of Novel Therapies
63. Reply to ‘Assembling the brain trust: the multidisciplinary imperative in neuro-oncology’
64. Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
65. Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis
66. Challenges and opportunities for physician-scientists in advancing cancer research
67. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study
68. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study
69. There's a Time and a Place for MYCN
70. A Mouse Model of the Most Aggressive Subgroup of Human Medulloblastoma
71. The miR-17~92 Cluster Collaborates with the Sonic Hedgehog Pathway in Medulloblastoma
72. An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma
73. The G protein α subunit G[α.sub.s] is a tumor suppressor in Sonic hedgehog-driven medulloblastoma
74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
75. Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation
76. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study
77. EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS
78. Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion– positive supratentorial ependymomas
79. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
80. Molecular subgroups of medulloblastoma: the current consensus
81. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
82. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups
83. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma
84. C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma
85. Molecular profiling of pediatric brain tumors: Insight into biology and treatment
86. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation
87. Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas
88. ZFTA Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors
89. ZFTA–RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma
90. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
91. Maturation Block in Childhood Cancer
92. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): A Pediatric Brain Tumor Consortium Study (PBTC-022)
93. A Perivascular Niche for Brain Tumor Stem Cells
94. Molecular Biology of Medulloblastoma: Will It Ever Make a Difference to Clinical Management?
95. Harnessing brain development to understand brain tumours
96. MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA
97. MODL-08. OPTIMIZATION OF A NOVEL LOCAL DELIVERY SYSTEM FOR THE TREATMENTS OF SUPRATENTORIAL EPENDYMOMA
98. EPEN-14. GENERATION OF A C11orf95-RELA FUSION TARGETING ANTIBODY AS A DIAGNOSTIC TOOL FOR SUPRATENTORIAL EPENDYMOMA
99. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A childrenʼs oncology group phase 1 consortium study
100. Introduction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.